Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Auris Medical Holding AG

http://www.aurismedical.com

Latest From Auris Medical Holding AG

MTI Outlook 2020: Medtechs Enter The Decade Of Digital, Consumers and Wellness

For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

Commercial Innovation

People Round-Up: Dipharma And Xellia North America Get New Heads

Dipharma appoints a new CEO, Xellia gets a new commercial head in North America, promotions are made at Lek, GVK Bio and the APhA, while appointments are seen at Auris Medical and Tris Pharma.

Appointments Strategy

Pharma Wakes Up To Transformative Progress In Hearing Loss Research

The cacophony of noise in the modern world is one factor driving the loss of hearing throughout humankind, a condition that until now has not been thought amenable to pharmacological intervention. But with small-molecule approaches to regenerating cells in the inner ear bearing fruit, biotech and pharmaceutical companies are taking renewed interest in the sector. 

Innovation Research and Development Strategies

Pharma Wakes Up To Transformative Progress In Hearing Loss Research

The cacophony of noise in the modern world is one factor driving the loss of hearing throughout humankind, a condition that until now has not been thought amenable to pharmacological intervention. But with small-molecule approaches to regenerating cells in the inner ear bearing fruit, biotech and pharmaceutical companies are taking renewed interest in the sector. 

Research and Development Strategies Research & Development
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Auris Medical AG
    • Auris Medical Ltd.
    • Auris Medical Holding Ltd.
    • Auris Medical Inc.
    • Zilentin AG
    • Zilentin Ltd.
UsernamePublicRestriction

Register